81 related articles for article (PubMed ID: 11786043)
1. Combination genetic therapy to inhibit HIV-1.
Strayer DS; Branco F; Landré J; BouHamdan M; Shaheen F; Pomerantz RJ
Mol Ther; 2002 Jan; 5(1):33-41. PubMed ID: 11786043
[TBL] [Abstract][Full Text] [Related]
2. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.
Cordelier P; Kulkowsky JW; Ko C; Matskevitch AA; McKee HJ; Rossi JJ; Bouhamdan M; Pomerantz RJ; Kari G; Strayer DS
Gene Ther; 2004 Nov; 11(22):1627-37. PubMed ID: 15295615
[TBL] [Abstract][Full Text] [Related]
3. SV40-derived vectors provide effective transgene expression and inhibition of HIV-1 using constitutive, conditional,and pol III promoters.
Jayan GC; Cordelier P; Patel C; BouHamdan M; Johnson RP; Lisziewicz J; Pomerantz RJ; Strayer DS
Gene Ther; 2001 Jul; 8(13):1033-42. PubMed ID: 11438838
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting AIDS in the central nervous system: gene delivery to protect neurons from HIV.
Cordelier P; Van Bockstaele E; Calarota SA; Strayer DS
Mol Ther; 2003 Jun; 7(6):801-10. PubMed ID: 12788654
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection.
BouHamdan M; Duan LX; Pomerantz RJ; Strayer DS
Gene Ther; 1999 Apr; 6(4):660-6. PubMed ID: 10476226
[TBL] [Abstract][Full Text] [Related]
6. Foamy virus vectors expressing anti-HIV transgenes efficiently block HIV-1 replication.
Taylor JA; Vojtech L; Bahner I; Kohn DB; Laer DV; Russell DW; Richard RE
Mol Ther; 2008 Jan; 16(1):46-51. PubMed ID: 17955023
[TBL] [Abstract][Full Text] [Related]
7. Using gene delivery to protect HIV-susceptible CNS cells: inhibiting HIV replication in microglia.
Cordelier P; Strayer DS
Virus Res; 2006 Jun; 118(1-2):87-97. PubMed ID: 16414141
[TBL] [Abstract][Full Text] [Related]
8. Efficient gene transfer to hematopoietic progenitor cells using SV40-derived vectors.
Strayer DS; Pomerantz RJ; Yu M; Rosenzweig M; BouHamdan M; Yurasov S; Johnson RP; Goldstein H
Gene Ther; 2000 May; 7(10):886-95. PubMed ID: 10845727
[TBL] [Abstract][Full Text] [Related]
9. Spleen necrosis virus-based vector delivery of anti-HIV-1 genes potently protects human hematopoietic cells from HIV-1 infection.
Marusich EI; Parveen Z; Strayer D; Mukhtar M; Dornburg RC; Pomerantz RJ
Virology; 2005 Feb; 332(1):258-71. PubMed ID: 15661158
[TBL] [Abstract][Full Text] [Related]
10. Gene transfer to the rhesus monkey brain using SV40-derived vectors is durable and safe.
Louboutin JP; Marusich E; Fisher-Perkins J; Dufour JP; Bunnell BA; Strayer DS
Gene Ther; 2011 Jul; 18(7):682-91. PubMed ID: 21368898
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of HIV-1 replication and infectivity by expression of a fusion protein, VPR-anti-integrase single-chain variable fragment (SFv): intravirion molecular therapies.
BouHamdan M; Kulkosky J; Duan LX; Pomerantz RJ
J Hum Virol; 2000; 3(1):6-15. PubMed ID: 10774802
[TBL] [Abstract][Full Text] [Related]
12. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis.
Agrawal L; Louboutin JP; Reyes BA; Van Bockstaele EJ; Strayer DS
Gene Ther; 2006 Dec; 13(23):1645-56. PubMed ID: 16871233
[TBL] [Abstract][Full Text] [Related]
13. Targeting CCR5 with siRNAs: using recombinant SV40-derived vectors to protect macrophages and microglia from R5-tropic HIV.
Cordelier P; Morse B; Strayer DS
Oligonucleotides; 2003; 13(5):281-94. PubMed ID: 15000819
[TBL] [Abstract][Full Text] [Related]
14. Long-term gene expression in dividing and nondividing cells using SV40-derived vectors.
Strayer DS; Agrawal L; Cordelier P; Liu B; Louboutin JP; Marusich E; McKee HJ; Ren CN; Strayer MS
Mol Biotechnol; 2006 Oct; 34(2):257-70. PubMed ID: 17172671
[TBL] [Abstract][Full Text] [Related]
15. Strategies for CNS-directed gene delivery: in vivo gene transfer to the brain using SV40-derived vectors.
Louboutin JP; Reyes BA; Agrawal L; Van Bockstaele E; Strayer DS
Gene Ther; 2007 Jun; 14(12):939-49. PubMed ID: 17443215
[TBL] [Abstract][Full Text] [Related]
16. Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication.
Klimatcheva E; Planelles V; Day SL; Fulreader F; Renda MJ; Rosenblatt J
Mol Ther; 2001 Jun; 3(6):928-39. PubMed ID: 11407907
[TBL] [Abstract][Full Text] [Related]
17. Antiviral potency of drug-gene therapy combinations against human immunodeficiency virus type 1.
Junker U; Baker J; Kalfoglou CS; Veres G; Kaneshima H; Böhnlein E
AIDS Res Hum Retroviruses; 1997 Nov; 13(16):1395-402. PubMed ID: 9359659
[TBL] [Abstract][Full Text] [Related]
18. Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication.
Bahner I; Sumiyoshi T; Kagoda M; Swartout R; Peterson D; Pepper K; Dorey F; Reiser J; Kohn DB
Mol Ther; 2007 Jan; 15(1):76-85. PubMed ID: 17164778
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of HIV-1 infection by down-regulation of the CXCR4 co-receptor using an intracellular single chain variable fragment against CXCR4.
BouHamdan M; Strayer DS; Wei D; Mukhtar M; Duan LX; Hoxie J; Pomerantz RJ
Gene Ther; 2001 Mar; 8(5):408-18. PubMed ID: 11313818
[TBL] [Abstract][Full Text] [Related]
20. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy.
Li MJ; Kim J; Li S; Zaia J; Yee JK; Anderson J; Akkina R; Rossi JJ
Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
